Therefore, PU.1-altered B-lymphoma cells conferred to lenalidomide resistance, which could be overcome by combined treatment of PD-L1 and 4-1BB antibody through modulating PD-1/PD-L1 and 4-1BB/4-1BBL-mediated lymphoma cell interaction with DC. Here, TNFRSF9 is linked to lymphoma.